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Introduction
African trypanosomes evade mammalian immune responses by an
extreme capacity for antigenic variation (McCulloch, 2004). The
parasite surface is completely covered by a dense monolayer of
protein tethered to the cell surface by a glycophosphatidyl inositol
anchor. This coat, composed of variant surface glycoprotein (VSG),
is homogeneous such that only one antigenic variant is expressed
at a time on any given parasite. Periodically, antibody responses to
the predominant VSG cause complement-mediated lysis of the
majority of parasites, followed by outgrowth of parasites that have
switched to a distinct antigenic variant. This results in the undulating
waves of parasitaemia that are characteristic of trypanosome
infections.
A further contributor to the undulating profile of a trypanosome
infection is the developmental regulation of proliferation status.
Early in each wave of parasitaemia, trypanosomes multiply rapidly
as morphologically slender forms. However, as parasite numbers
increase, an unidentified parasite-derived signal (stumpy induction
factor; SIF) stimulates growth arrest in G1 (Vassella et al., 1997).
This quorum sensing (QS) mechanism induces the developmental
switch to morphologically stumpy forms, which do not divide,
thereby limiting the increase in parasite numbers and promoting
the generation of a chronic infection (Lythgoe et al., 2007).
Although stumpy forms are irreversibly committed to cell division
arrest in the bloodstream, this does not represent a simple example
of self-destructive cooperation, as seen in some bacterial
populations (Ackermann et al., 2008; Gardner and Kummerli,
2008). Rather, the stumpy forms are adapted for life-cycle
progression via their transmission to tsetse flies, the vector for
African trypanosomiasis (Dean et al., 2009; Engstler and Boshart,
2004; Tasker et al., 2000). In particular, only stumpy forms in the
bloodstream parasite population express members of a surface
transporter family of proteins (PAD proteins) that allow detection
of the citrate/cis-aconitate differentiation signal upon transmission
to tsetse flies (Dean et al., 2009). This is assisted by
developmentally regulated and thermoregulated protein trafficking
to the parasite surface that is characteristic of stumpy forms
(Engstler and Boshart, 2004). Also, stumpy forms are relatively
resistant to proteolytic assault in the tsetse midgut and to other
stresses that rapidly result in the killing of slender forms (Nolan et
al., 2000; Sbicego et al., 1999). Combined with the enhanced
resistance of stumpy forms to the developing antibody response in
the mammalian host via hydrodynamic flow (Engstler et al., 2007),
these characteristics enable trypanosome populations to achieve a
balance between rapid establishment and maintenance of the
parasitaemia, development of a sustained long-term infection and
optimisation of their transmission potential.
Long-term laboratory passage of trypanosome lines without
tsetse transmission produces monomorphism, i.e. the selection of
parasites that have lost the capacity to generate stumpy forms in
vivo and that are analogous to QS signal-blind mutants in bacteria
(Diggle et al., 2007). These have provided useful experimental
tools because they exhibit a reduced frequency of antigen switching
(Robinson et al., 1999), enabling analysis of the underlying
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Summary
Trypanosomes evade host immunity by exchanging variant surface glycoprotein (VSG) coats. VSG genes are transcribed from
telomeric expression sites, which contain a diverse family of expression-site-associated genes (ESAGs). We have discovered that the
mRNAs for one ESAG family, ESAG9, are strongly developmentally regulated, being enriched in stumpy forms, a life-cycle stage in
the mammalian bloodstream that is important for the maintenance of chronic parasite infections and for tsetse transmission. ESAG9
gene sequences are highly diverse in the genome and encode proteins with weak similarity to the massively diverse MASP proteins
in Trypanosoma cruzi. We demonstrate that ESAG9 proteins are modified by N-glycosylation and can be shed to the external milieu,
this being dependent upon coexpression with at least one other family member. The expression profile and extracellular release of
ESAG9 proteins represents a novel and unexpected aspect of the transmission biology of trypanosomes in their mammalian host. We
suggest that these molecules might interact with the external environment, with possible implications for infection chronicity or
parasite transmission.
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molecular regulation of antigenic variation. Studies of these lines
have revealed that VSG genes are always expressed from telomeric
expression sites, of which only one of about 25 possible sites is
active at any one time (Borst, 2002). The active expression site is
apparently selected through association with an expression site
body at the nuclear envelope (Navarro and Gull, 2001). VSG
expression sites have a conserved overall structure (Hertz-Fowler
et al., 2008). Upstream of the VSG gene itself are a number of
expression-site-associated genes (ESAGs) (Cully et al., 1985; Pays
et al., 2001). These are co-transcribed with the VSG gene by RNA
polymerase I (Gunzl et al., 2003), the promoter being positioned
45–60 kb upstream (Kooter et al., 1987; Pays et al., 1989). The
function of ESAGs is largely unknown, although the products of
ESAG6 and ESAG7 form a heterodimeric transferrin receptor (Bitter
et al., 1998; Salmon et al., 1994; Schell et al., 1991), and ESAG4
encodes an adenylate cyclase activity (Pays et al., 1989). Also,
bioinformatic analysis of ESAG5 protein suggests that it bears
similarity to a human lipid binding/lipid transfer family of proteins
(Barker et al., 2008). In addition, Trypanosoma brucei rhodesiense
express an unusual ESAG, SRA, which confers resistance to an
innate immune component of human serum, ApoL-1 (Vanhamme
et al., 2003; Xong et al., 1998). Thus, where characterised, ESAGs
are involved in host–parasite interactions unrelated to antigenic
variation.
We have discovered that an unusual expression-site-associated
gene family, ESAG9, is developmentally regulated, being
specifically expressed only in stumpy forms. We demonstrate that
several ESAG9 genes are upregulated during the transition from
slender to stumpy forms in T. brucei, contrasting with the
monoallelic expression characteristic of VSG genes. Surprisingly,
we find that ESAG9 protein can be shed from slender form parasites
when ectopically coexpressed with another ESAG9 copy.
Confirming the biological relavence of this, ESAG9 proteins are
also shed by wild-type stumpy cells generated in vivo. Our results
demonstrate that ESAG9 proteins are stumpy stage-specific
molecules implicated in trypanosome chronicity or transmission
biology.
Results
Developmental expression of a VSG expression-site-
associated gene
Previous analyses have demonstrated that tsetse-transmission
competence requires the development of bloodstream stumpy forms
(Dean et al., 2009; Robertson, 1912; Tasker et al., 2000; Wijers and
Willett, 1960). To understand the molecular characteristics of
stumpy forms we used cDNA subtraction selection to identify
transcripts that differ in expression between isogenic monomorphic
slender (T. brucei EATRO 2340; GUP 2965) and stumpy forms (T.
brucei EATRO 2340; GUP2962), each expressing the same VSG
gene (GUTat 7.2) from the same VSG expression site. This resulted
in the selection for a number of stumpy-enriched transcripts, of
which the most frequently isolated were two members of the
ESAG9 family (Florent et al., 1991), represented by clones K9 and
K69. To confirm the differential expression of these transcripts,
northern blots of RNA derived from monomorphic slender (GUP
2965) and stumpy cells (GUP2962) and also from cultured
procyclic forms (T. brucei s427) were hybridised with riboprobes
for K9 and K69 and for the constitutively expressed transcript -
tubulin. Fig. 1A establishes that both K9 and K69 transcripts are
highly enriched in the stumpy samples, each being expressed at a
low level in monomorphic cells and absent in procyclic forms.
Hybridisation of cultured procyclic forms generated 7 days after
the in vitro differentiation of T. brucei EATRO 2340 GUP 2962
stumpy forms also generated very low expression, confirming that
the observed expression profile did not represent strain specific
differences between procyclic form parasites (data not shown).
The upregulation of ESAG9 transcripts in stumpy form cells has
also been recently confirmed by microarray analysis of different
life-cycle stages (Jensen et al., 2009; Kabani et al., 2009).
The precise biological relationship between laboratory-passaged
monomorphic forms and pleomorphic slender forms is not clear
(Matthews et al., 2004). Therefore, to assay the expression of K9
and K69 during the course of a pleomorphic trypanosome infection,
RNA was harvested when the parasites were at a density of less
than 2107/ml and >99% slender in morphology. Parasites were
also harvested at a density of 1108/ml but before the appearance
of significant numbers (i.e. <10%) of stumpy forms, this
representing an ‘intermediate form’ population. Finally, parasites
were harvested at 2108–5108/ml, when the population was
>90% stumpy by morphology. Fig. 1B demonstrates that K9 and
K69 were both almost undetectable in slender cells, but fully
upregulated in intermediate and stumpy forms. Thus, the mRNAs
for these ESAG9 family members are developmentally regulated in
bloodstream trypanosomes, being induced early in the transition to
stumpy forms prior to morphological transformation.
Genomic analysis of the ESAG9 gene family in T. brucei
Two closely related ESAG9 genes have been previously detected
in the equine parasite T. equiperdum (Florent et al., 1991). Although
monomorphic, these parasites are believed to be a recently diverged
subspecies of T. brucei (Claes et al., 2005; Lai et al., 2008). In T.
equiperdum, one ESAG9 gene was expressed from within the
BoTat 178 VSG expression site, whereas the other was transcribed
from a non-expression site location in a VSG-independent manner
(Florent et al., 1991). Analysis of the T. brucei TREU927/4 genome
database revealed that the ESAG9-K9 gene is located in a
chromosome internal position on chromosome 7 (Tb927.07.170)
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Fig. 1. Differential expression of ESAG9 transcripts. (A)Expression of
clones K9 and K69 analysed against total RNA derived from monomorphic
(M), or stumpy forms of pleomorphic T. brucei EATRO 2340 GUTat 7.2 (St)
and procyclic forms (Pc). A constitutively expressed transcript, -tubulin is
shown as a control. (B)Expression of K9 and K69 in slender (Sl), intermediate
(Int) and stumpy forms of pleomorphic T. brucei EATRO 2340. A control
constitutively expressed transcript is also shown. (C) Equivalent whole cell
protein samples of slender and stumpy forms of pleomorphic T. brucei EATRO
2340 probed with an anti-peptide antibody to ESAG9-K9. The protein
migrates at approximately 35 kDa, contrasting with a predicted molecular
mass of 27 kDa.
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
whereas the ESAG9-K69 gene is absent from the available genome
dataset. Although VSG expression sites are underrepresented, the
T. brucei genome database (available at http://www.geneDB.org)
contains 19 ESAG9 genes, of which ten are annotated as
pseudogenes. The annotated ESAG9 genes are each located at
chromosome-internal and subtelomeric positions, and each is
closely adjacent to other ESAGs, VSG genes or VSG pseudogenes.
Hence, ESAG9 genes appear to co-associate with VSG gene
expression sites, expression site components or expression site
relics, frequently at subtelomeric positions (diagrammatic
representations of the genomic location of several ESAG9 genes
are shown in supplementary material Fig. S1). In order to evaluate
whether ESAG9-K9 and ESAG9-K69 genes were also represented
in VSG expression sites, a TAR library comprising the cloned
telomeres of T. brucei EATRO 2340 (a kind gift of Gloria Rudenko,
University of Oxford, Oxford, UK) (Young et al., 2008) was
analysed for the presence of each gene copy using gene-specific
PCR primers. This demonstrated that neither K9 or K69 was found
associated with the cloned telomeric sequences (Fig. 2), although
Tb927.5.4620 (labelled ESAG9-EQ on Fig. 2 because it is the
gene most closely related to the T. equiperdum ESAG9 genes; see
below) was found on two TAR clones. This matches the expression
site location for the closest homologue of this gene in T. brucei
s427 in BES211 (Hertz-Fowler et al., 2008) (supplementary
material Fig. S1). Thus, ESAG9 sequences are occasionally found
within VSG expression sites, but neither ESAG9-K9 or ESAG9-
K69 were expressed from, nor located in, a VSG expression site in
the parasite strain examined.
Given the genomic distribution of ESAG9 genes within and
outside of VSG expression sites, we sought to analyse whether one,
two or a repertoire of several ESAG9 genes could be expressed in
T. brucei and whether the expression of each of these was stumpy-
enriched. Thus, the expression of ESAG9-K9, ESAG9-K69 and
three further ESAG9 genes identified in the T. brucei TREU 927/4
genome sequence (Tb927.3.5790, Tb927.5.4620 and Tb09.v1.0330)
were analysed in monomorphic slender and pleomorphic stumpy
forms of T. brucei GUTat 7.2, and in stumpy forms of a pleomorphic
line of T. brucei expressing VSG AnTat1.1. Fig. 3A demonstrates
that each line expressed more than one ESAG9 gene, with two of
the genes tested being expressed in both T. brucei GUTat 7.2 and
T. brucei AnTat1.1 (Tb09.v1. 0330; Tb927.5.4620), in each case
this expression was stumpy-enriched (Fig. 3A,B). By contrast,
Tb927.3.5790 was expressed in T. brucei AnTat 1.1 stumpy forms
but not in T. brucei EATRO 2340 slender or stumpy forms, whereas
ESAG9-K9 and ESAG9-K69 were expressed in T. brucei EATRO
2340 but not AnTat1.1. This reflected the presence or absence of
each gene: analysis of the genomic DNA of each line by PCR
demonstrated that Tb927.3.5790 was absent from T. brucei EATRO
3403ESAG9 developmental expression
Fig. 2. Analysis of T. brucei EATRO 2340 TAR clones for the presence of ESAG9 gene sequences. T. brucei EATRO 2340 genomic DNA (far left) and TAR
cloned bloodstream form expression sites (1–23, a gift from Gloria Rudenko) were analysed by PCR using gene-specific primers for the presence of the following
genes: Tb927.5.4620 (the gene most similar to the ESAG sequences in T. equiperdum), ESAG9-K9, ESAG9-K69 and ESAG6, which is present in every expression
site that has been sequenced so far. ESAG6 was indeed found to be in all expression sites, Tb927.5.4620 was in two expression sites (4 and 5) and ESAG9-K9 and
ESAG9-K69 were absent from all expression sites in T. brucei EATRO 2340.
Fig. 3. Expression of ESAG9 genes in T. brucei. (A)Expression profile of five ESAG9 genes on monomorphic slender (EATRO Sl) and pleomorphic stumpy
forms of T. brucei EATRO 2340 GUTat 7.2 (EATRO St) and pleomorphic stumpy forms of T. b. brucei AnTat1.1 (AnTat St). Loading of each lane is indicated by
the ethidium bromide-stained rRNAs. An ESAG2-specific riboprobe was also hybridised with the same RNA samples, as was a constitutively expressed control
transcript (Tb11.02.3640). (B)Stumpy-enriched expression of two ESAG9 genes expressed in both T. brucei EATRO 2340 and T. brucei brucei AnTat1.1. RNA
from pleomorphic slender (early parasitaemia) and stumpy (late parasitaemia) cells is shown for each line.
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2340 genomic DNA whereas ESAG9-K9 and ESAG9-K69 were
absent from the genome of T. brucei AnTat1.1 (data not shown).
Where present, therefore, the expression of all ESAG9 genes
tested was elevated in stumpy forms. Contrasting with this, a
control transcript (Tb11.02.3640) was expressed equally in slender
and stumpy forms of each line, as was another expression-site-
associated gene, ESAG2 (Fig. 3A). Moreover, ESAG9 expression
was not upregulated in bloodstream forms arrested in G2 by VSG-
specific RNAi ablation (Sheader et al., 2005; Gloria Rudenko,
personal communication), eliminating non-specific elevation of
ESAG9 mRNA upon cell cycle arrest, albeit in a distinct cell-cycle
stage to stumpy forms. We conclude that ESAG9 expression is
developmentally elevated in a stumpy-specific manner, that multiple
members of the ESAG9 family are upregulated upon the transition
to stumpy forms, and that different trypanosome lines express
distinct repertoires of these genes.
ESAG9 genes encode a diverse protein family with a
conserved motif
Fourteen intact ESAG9 genes have been identified in the genomes
of different trypanosome species and strains: T. brucei TREU927/4
(nine genes), T. brucei Lister 427 expression sites (one gene), T.
brucei EATRO 2340 (two genes; ESAG9-K9 and ESAG9-K69, the
latter also being present in TREU927/4), T. equiperdum (two genes)
and T. b. gambiense (one gene). No closely related sequences were
identified in the incomplete genomes of T. congolense or T. vivax.
To search ESAG9 proteins for motifs that suggest function, we
aligned the predicted protein sequences of all available intact
ESAG9 genes (supplementary material Fig. S2). Many of the
predicted ESAG9 proteins have relatively low identity (18–39%)
to each other and to the T. equiperdum proteins, demonstrating that
ESAG9s are a diverse protein family. However, one T. brucei
TREU927/4 ESAG9 member (Tb927.5.4620) and the ESAG9
encoded in an expression site in T. brucei Lister 427
(Tb427.BES122.10) were highly homologous to each other (88%
identity) and to the genes previously characterised in T. equiperdum
(ESAG9u, ESAG9c). Tb927.5.4620 exhibited 67 and 84% identity
with ESAG9u and ESAG9c of T. equiperdum, respectively, and
Tb427.BES122.10 exhibited 69 and 85% identity, respectively. It
appears therefore that ESAG9 proteins are very diverse as a family,
and yet can be well conserved between different trypanosome
species. PSI-BLAST searches did not reveal the presence of
ESAG9-related proteins in any other species, although searches
against other kinetoplastid genomes frequently recognised at low
similarity (e-value  410–5–0.028, with a typical value of 0.001)
distinct T. cruzi MASP proteins, which are members of a large and
diverse mucin glycoprotein superfamily of unknown function
(Bartholomeu et al., 2009). The weak similarity was restricted to
the central diverse core of MASP proteins, distinct from their
conserved C-terminal region.
Although the ESAG9 proteins are diverse, a restricted region of
conservation was observed near the N-terminus of each protein.
Thus, approximately 10–20 amino acids after the predicted cleavage
site of the N-terminal signal sequence, there exists the motif
CX3WX8CX5G, which is highly conserved among the ESAG9
family. Searching available sequence databases for proteins that
share this motif identified a related sequence conserved among
members of the protein phosphatase PP2C family (supplementary
material Fig. S3), these residues being required for Mn2+-binding
and functional activity of these enzymes (Barford et al., 1998;
Kusuda et al., 1998). Similarity to this conserved motif was also
observed in members of the SRCR family of scavenger receptors.
Outside of this region, however, no further extensive similarity to
these or other proteins was detected.
Protein expression and ectopic protein expression of
ESAG9-K9 and ESAG9-K69
To evaluate whether the observed differential mRNA profile of the
ESAG9 genes was matched at the protein level, an antibody was
raised against a peptide sequence specific for ESAG9-K9 (NH2-
QVHDGEQRDLEGRGC), this being located at a position not
conserved in other ESAG9 family members (supplementary
material Fig. S2). When this antibody was reacted with protein
samples from monomorphic slender and stumpy forms, a protein
of ~35 kDa was detected specifically in stumpy parasites (Fig. 1C).
This was slightly larger than the molecular mass predicted from
the primary ESAG9-K9 amino acid sequence (27 kDa), suggesting
possible posttranslational modification of the protein (see below).
The expression profile of ESAG9-K9 was also examined during
the synchronous differentiation of a homogenous population of
stumpy form parasites to procyclic forms in vitro. Thus, stumpy
cells were harvested from a rodent infection and differentiation of
the cells to procyclic forms was initiated with cis-aconitate and
protein samples prepared at 3 hourly intervals up to 15 hours, and
then after 30 hours. Under these conditions, the VSG coat was
maintained for 3–6 hours, but significantly decreased thereafter,
matching the expected kinetics for this differentiation event
(Matthews and Gull, 1994; Ziegelbauer and Overath, 1990) (Fig.
4A). By contrast, ESAG9-K9 was detected weakly in stumpy
form cell extracts but enriched between 3–9 hours after the
initiation of differentiation, and undetectable beyond 15 hours.
Immunofluorescence assay of cells 6 hours after the initiation of
differentiation confirmed ESAG9-K9 expression on differentiating
cells, with the staining being dispersed in a punctate pattern with
concentration around the nucleus and, in some instances, a signal
from the flagellar pocket region or closely associated structures
(Fig. 4B). The punctate staining profile was reminiscent of the
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Fig. 4. Expression profile of ESAG9-K9 during differentiation to procyclic
forms. (A)ESAG9 expression during stumpy–procyclic form differentiation.
Stumpy forms of T. brucei EATRO 2340 were induced to differentiate to
procyclic forms. Analysis of the Coomassie Blue stained gel shows that the
VSG runs at approximately 50 kDa and is lost between 3 and 6 hours. The
same protein samples were probed with anti-peptide antibody to ESAG9-K9
and trypanosome -tubulin. (B)Cells harvested 6 hours after the initiation of
differentiation and probed with antibody to ESAG9-K9 and EP procyclin (to
demonstrate differentiation). A DAPI stained image of the same cell is also
shown.
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trypanosome endoplasmic reticulum distribution, which was
explored further using a transgenic cell line (see below). In contrast
to ESAG9-K9, an anti-peptide antibody raised against ESAG9-
K69 reacted very poorly with either stumpy cells or cells
undergoing differentiation such that its expression and cellular
localisation could not be determined.
Expression analysis of ESAG9 proteins in transgenic
bloodstream forms
The transient or low level expression of ESAG9 proteins rendered
them difficult to study in stumpy cells or parasites undergoing
differentiation. Therefore, to assist characterisation of these
proteins, we generated monomorphic bloodstream cells
engineered to express either ESAG9-K9 or ESAG9-K69 under
tetracycline regulation. To aid detection, but to avoid perturbation
of potential N-terminal or C-terminal targeting signals, an internal
epitope tag sequence, the ten amino acid Ty1 tag (Bastin et al.,
1996), was incorporated into each gene at an equivalent position
to replace the ten amino acids internal to either ESAG9-K9 (amino
acids 64–73; generating cell line BSF ESAG9-K9-Ty) or ESAG9-
K69 (amino acids 55–64; generating cell line BSF ESAG9-K69-
Ty), this region having no clear conservation between distinct
ESAG9 gene copies (supplementary material Fig. S2). An
expression construct was also generated containing an untagged
copy of ESAG9-K9, detectable with the K9-specific antibody, to
eliminate any potential disruption of ESAG9 caused by the epitope
tag sequence. Finally, to match the observed coexpression of
these genes in T. brucei EATRO2340 stumpy forms, we generated
a further cell line capable of the simultaneous inducible expression
of both untagged ESAG9-K9 and Ty1-tagged ESAG9-K69
(generating cell line BSF K9:K69).
After selection and the induction of transgene expression with
tetracycline, K9 and K69 transcripts were generated at levels
equivalent to (K9), or less than (K69), endogenous levels of these
transcripts in T. brucei EATRO 2340 stumpy forms (Fig. 5A). This
indicated that overexpression artefacts were unlikely to contribute
to any functional analyses. At the protein level, ectopically
expressed ESAG9 proteins were detectable from cell lines
expressing ESAG9-K9 (untagged and Ty1 tagged) and ESAG9-
K69-Ty1 (Fig. 5B). In the double-expresser BSF K9:K69 cell line,
ESAG9-K9 was expressed but ESAG9-K69 was barely detectable
in the cell lysate because it is released from the cells (see later).
The molecular mass at which ESAG9-K69 protein migrated varied
between the BSF K69 cell line, where it ran at 50 kDa, and the
BSF K9:K69 cell line, where the ESAG9-K69 ran at 42 kDa, both
higher than the predicted molecular mass of 26 kDa for this protein.
In cell line BSF-K9-Ty, ESAG9-K9 migrated at the same molecular
mass as the endogenous protein in stumpy forms, indicating
appropriate processing and possible posttranslational modification.
Moreover, by immunofluorescence, the punctate expression
observed in differentiating cells (Fig. 4D) was also detectable in
this cell line with the Ty-tag specific antibody. This signal matched
that of the ER marker BiP (a gift of Jay Bangs, University of
Wisconsin, Madison, WI), and precise colocalisation of the two
proteins was observed using confocal microscopy (Fig. 5D).
Apparently, the ectopic expression of ESAG9-K9 in monomorphic
slender cells faithfully reproduces the expression and location of
this protein in pleomorphic stumpy and differentiating cells. The
ectopic expression of the different ESAG9 proteins, however, had
no effect on parasite growth in vitro (supplementary material Fig.
S4) or in vivo (data not shown).
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Fig. 5. Secretion of ESAG9 proteins. (A)Northern blots of the mRNA levels
of ESAG-K9 (no tag) and ESAG9-K69-Ty in transgenic T. brucei s427
monomorphic forms. In each case probes were used that detected either the
endogenous ESAG9 transcript only (this being directed to the 3UTR missing
in the transgenes) or to the open reading frame (ORF; detecting both the
endogenous and ectopically expressed copy). The gene for ESAG9-K9 is
present in T. brucei s427 and the low level expression of this gene is detected
in the monomorphic slender forms. By contrast, the gene for ESAG9-K69 is
absent from the T. brucei s427 genome and no endogenous transcript is
detected. The respective levels of ESAG9-K9 and ESAG9-K69 are also shown
in early intermediate (In) and stumpy (St) forms of T. brucei EATRO 2340
(lanes 8, 9). Tetracycline-inducible expression of ESAG9-K9 (lanes 2, 3),
ESAG9-K69 (lane 4,5) and both ESAG9-K9 and K69 is detected in the single
and double expresser lines, though the ESAG-K69 transgene expression is
leaky in the double expresser. The ESAG9-K69 generates two mRNAs
believed to represent the use of alternative polyadenylation sites in the
expression construct. (B)Ectopic expression of ESAG9-K9 (no tag, or Ty-
tagged) and of ESAG9-K69, or both proteins, in monomorphic bloodstream
forms of T. brucei. Protein samples were derived from cells harvested after 48
hours with (+) or without (–) tetracycline (to induce transgene expression) and
probed for expression of each protein using either ESAG9-K9-specific
antiserum (K9-no tag samples and BSF K9:K69) or the Ty1-specific antibody,
BB2. Relative loading was verified by Coomassie Blue staining or reaction
with antibody to -tubulin. In the BSF K9:K69 cell line, ESAG9-K69
expression was barely detectable due to its extracellular release (see Fig. 7).
(C)Colocalisation of Ty-tagged ESAG9-K9 in BSF K9-Ty cells with an ER
marker, BIP. The localisation of ESAG9-K9 (left) (detected using the BB2
antibody) and BIP (centre) were analysed using confocal microscopy. In the
overlaid image (right; yellow) extensive colocalisation was evident. Scale bar:
15m.
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Initially, the transgenic cell lines were used to assess post-
translational modifications of the ESAG9 proteins. In the first
instance, we examined the potential for GPI anchor addition to
ESAG9-K9, a modification predicted by the D-GPI and GPI-SOM,
but not Big-PI, algorithms. This was evaluated by submitting the
cells to hypotonic lysis under conditions where the parasite GPI-
PLC induces the release of mature GPI-anchored proteins into the
supernatant. As a control, we monitored the release of the GPI-
anchored VSG 221 protein expressed on the transgenic cell line.
Fig. 6A demonstrates that ESAG9-K9 remained cell-associated
upon hypotonic lysis whereas the VSG control was very rapidly
released into the soluble fraction, indicating that the ESAG9-K9
protein was either not GPI anchored in these cells or that GPI-PLC
could not gain access to the protein. Hypotonic release of ESAG9-
K9 from stumpy forms of T. brucei EATRO 2340 was also not
observed, although in that case VSG release could not be verified
due to the absence of a suitable VSG-specific antibody (data not
shown).
In addition to GPI addition, the potential for N-glycosylation
was evaluated for ESAG9-K9 and ESAG9-K69, each of which
were predicted to contain this modification at either three positions
(ESAG9-K9) or two positions (ESAG9-K69). Thus, cell lysates
from monomorphic bloodstream form cells ectopically expressing
either ESAG9-K9 or ESAG9-K69 were subjected to treatment
with peptide N-glycosidase F (PNGase F) enzyme, and the
migration of the ectopically expressed protein examined (Fig. 6B).
This demonstrated that ESAG9-K9 ran approximately 4 kDa lower
after treatment, whereas ESAG9-K69 ran approximately 2 kDa
lower. These size changes are compatible with the presence of
either two or one glycan chains, respectively, assuming that these
glycans are of a high-mannose type (because of the ER localisation),
generating an approximate mass of 1700–1900 Da (Jones et al.,
2005).
ESAG9 proteins are secreted
Examination of the cell line expressing ESAG9-K9 and ESAG9-
K69 together (BSF K9:K69) revealed the expression of barely
detectable ESAG9-K69 by western blotting using the Ty1-specific
antibody BB2, despite the detectable (though weak) expression of
ESAG9-K9 (Fig. 5B). However, immunofluorescence using the
BB2 antibody revealed an occasional signal from the flagellar
pocket of fixed cells and a clear corona of staining visible on the
slide surrounding the cells (Fig. 7A). This suggested that ESAG9-
K69 protein was being released from the parasites. To investigate
this, conditioned media from the BSF-K69 and BSF K9:K69 cell
line was subjected to immunoprecipitation using the BB2 antibody,
in order to select the Ty1 epitope-tagged ESAG9-K69 protein. To
ensure specificity, a blocking peptide control was also used that
binds to the BB2 antibody and thereby prevents it from recognising
the Ty tag. This immunoprecipitation analysis generated a clear
signal from the BSF K69 line associated with the cell pellet, but
not from the medium, demonstrating an absence of detectable
protein release from this cell line (Fig. 7B). By contrast, however,
the same analysis using the BSF K9:K69 cell line, expressing both
ESAG9-K9 and ESAG9-K69, demonstrated that ESAG9-K69
protein was released to the cell medium, with no detectable cell-
associated signal (Fig. 7C). To eliminate the possibility that the
released protein was a consequence of cell lysis, a parallel
immunoprecipitation was also carried out using an antibody specific
for the cytoplasmic RNA binding protein, TbZFP3, again in the
presence or absence of an anti-TbZFP3 blocking peptide to ensure
specificity (intracellular control; Fig. 7C). In this case, TbZFP3
was exclusively selected from the cellular fraction, demonstrating
cellular integrity under the selection conditions used.
The ectopic expression of proteins in transgenic parasites has
the potential to generate aberrant location or trafficking properties
in the expressed protein. Therefore, we assessed the potential
secretion of ESAG9-K69 in T. brucei EATRO 2340 cells using the
anti-peptide antibody specific for that protein. Thus, stumpy cells
were harvested from a mouse infection, purified by DE52
chromatography and incubated for 4 hours in serum-free medium,
in order to permit effective accumulation of released proteins.
Thereafter, the stumpy-conditioned medium was concentrated 1300-
fold by using a 10 kDa Mr vivaspin column and the relative
distribution of ESAG9-K69 between the conditioned medium and
cellular fraction determined (Fig. 7D). As before, an antibody to
an intracellular marker protein, in this case HSP70, was assessed
simultaneously to indicate the extent of released protein attributable
to cell lysis. Although some release of HSP70 was evident in the
conditioned medium, as expected after incubation of recently
harvested stumpy forms maintained under serum-free conditions,
the ESAG-K69 was found to be preferentially concentrated in the
medium fraction, with approximately tenfold enrichment with
respect to the intracellular HSP70 control (i.e. 39.4 and 4.4%,
respectively, release into the medium, accounting for the cell
number equivalents in the assay). Reactivity of the same samples
with antibody to ESAG9-K9 also revealed an enrichment of that
protein in the extracellular fraction. Interestingly, however, much
of this protein migrated at 36 and 50 kDa, the latter matching the
migration of ESAG9-K69. These higher molecular mass forms
might represent hetero- or homodimerisation of the expressed
ESAG9 proteins or represent protein aggregation during medium
3406 Journal of Cell Science 123 (19)
Fig. 6. Post-translational modifications of ESAG9 proteins. (A)Hypotonic
lysis of BSF K9 cells. Cells induced to ectopically express ESAG9-K9 were
harvested and incubated in hypotonic lysis buffer for 0, 5 or 10 minutes and
then centrifuged to separate the pellet (P) and supernatant (S) fractions. The
samples were analysed by western blotting, which revealed that the VSG was
released into the supernatant by the action of endogenous GPI-PLC enzyme
even at the zero minutes, whereas ESAG9-K9 remained associated with the
cell pellet. The Coomassie Blue-stained gel demonstrates the relative
abundance of proteins in the S and P fractions. (B)N-Glycosylation of ESAG9
proteins. Monomorphic bloodstream form cells expressing either ESAG9-K9
or ESAG9-K69 were subjected to enzymatic digestion with PNGaseF (+), and
controls were incubated for the same length of time in digestion buffer without
the addition of enzyme (–). Western blotting with BB2 antibody indicated that
ESAG9-K9 changed size by approximately 4 kDa as a result of enzyme
treatment, and ESAG9-K69 by 2 kDa.
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
concentration, a phenomenon sometimes observed with
glycosylated proteins (data not shown).
We conclude the ESAG9-K9 and ESAG9-K69 can be secreted
by trypanosomes. Moreover, analysis in transgenic bloodstream
form lines demonstrated that the release of ESAG9-K69 was
dependent upon the coexpression of at least one other ESAG9
protein, ESAG9-K9.
Consequences of ESAG9 secretion in vitro and ex vivo
The release of ESAG9 protein by stumpy forms suggested a
potential role in either optimising transmission or in interactions
with the mammalian immune system. Because stumpy forms
express a large and diverse family of ESAG9 transcripts (Fig. 3),
RNAi-mediated ablation of the expression of all family members
was not feasible. Moreover, the inability of these monomorphic
lines to establish in tsetse flies (our unpublished observations)
restricted our ability to assay transmission in vivo. Hence, we
exploited available in vitro and ex vivo assays to assess the
consequences of ESAG9 secretion for parasite survival, and to
monitor any effects on mammalian immune function.
One factor potentially important in parasite survival during
transmission is the resistance of the differentiating parasite to
complement in the blood meal, which in mosquitos remains active
for 6 hours or more (Margos et al., 2001). In tsetse, this time
coincides with the loss of the trypanosome VSG coat, which
ordinarily protects the bloodstream trypanosomes from complement
activated by the alternative pathway. Therefore, to assess whether
ESAG9 protein could protect parasites from complement during
tsetse infection, procyclic form trypanosomes were incubated with
the conditioned medium from BSF K9:K69 cells in the presence of
either Guinea Pig serum (GPS; as a source of complement) or heat-
inactivated Guinea Pig or foetal calf serum (HI-GPS, HI-FCS), as
controls. The viability of each population was then assessed over
24 hours in an Alamar Blue viability assay. Supplementary material
Fig. S5 demonstrates that GPS effectively blocked procyclic form
growth when compared to either HI-GPS or HI-FCS, as expected.
However, no difference was observed in the presence of BSF
K9:K69 conditioned medium. A titration of GPS also revealed no
protective effect of ESAG9 protein in the cell culture medium
(supplementary material Fig. S6), confirming that exogenous
ESAG9 K9:K69 does not render procyclic form parasites resistant
to complement-mediated lysis under the assay conditions used.
To assess the potential effects of ESAG9 in the mammalian
host we used an ectopic expression approach in the monomorphic
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Fig. 7. Location of ESAG9-K69 protein in BSF K9:K69 cells engineered to express both ESAG9-K9 and ESAG9-K69 concurrently. (A)The ESAG9-K69
was detected using BB2 antibody and is visible in some cells as a signal from, or nearby, the flagellar pocket (white arrowheads) and also as a speckled staining on
the slide itself. (B)Immunoprecipitation from cell lysate and conditioned media of monomorphic cells ectopically expressing ESAG9-K69. Immunoprecipitation
was carried out with the BB2 antibody, which recognises the Ty epitope tag in the ESAG9-K69 sequence, in the presence (block) or absence (no block) of blocking
peptide. Samples were analysed by western blotting using the BB2 antibody. There was a strong signal for ESAG9-K69 from the cell lysate in the absence of
blocking peptide. (C)Immunoprecipitation from cell lysate (LY) and conditioned media (CM) of monomorphic cells ectopically expressing both ESAG9-K9 and
ESAG9-K69. Immunoprecipitation was carried out with either BB2 antibody that recognises the Ty epitope tag in the ESAG9-K69 sequence, or anti-TbZFP3
antibody, which is an intracellular control, in the presence or absence of blocking peptides. Samples were analysed by western blotting using the respective
antibodies. There was a strong signal for the intracellular control in the cell lysate in the absence of ZFP3 blocking peptide (no block), and no signal from the
conditioned media . There was a strong signal for ESAG9-K69 from the conditioned media in the absence of blocking peptide and no signal from the cell lysate.
Conditioned media from T. brucei EATRO 2340 stumpy form cells. (D)Stumpy form cells were harvested from a mouse 6 days post-innoculation and incubated in
serum-free media. The conditioned media was then concentrated and analysed by western blotting with ESAG9-K69, Hsp70 (a control for cell integrity) and
ESAG9-K9 antibodies. For all antibodies, there was a signal from both the cell lysate and concentrated conditioned media lanes. However, the signal from the CM
lanes was much stronger for ESAG9-K69 and ESAG9-K9 than for Hsp70. Size markers are in kDa.
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lines that do not normally express ESAG9. Hence, the BSF
K9:K69 cell line was grown in mice administered either without,
or with, doxycycline (DOX) in their drinking water to induce
ectopic ESAG9 expression. Transgene expression was confirmed
at the transcript level by northern blotting of mRNA derived from
the in vivo grown parasites, this indicating tightly inducible and
close to physiological levels of K9 expression and
subphysiological, leaky expression of K69 when compared to T.
brucei EATRO 2340 stumpy forms (supplementary material Fig.
S7). As controls, mice were alternatively infected with the parental
monomorphic cell line or were injected with HMI-9 medium,
these mice being subsequently supplied with, or without, DOX in
their drinking water. Initially, in the trypanosome-infected mice,
the progression of the parasitaemia over approximately 5 days
was assayed. This revealed no consistent difference in the overall
virulence of the respective parasite lines. Thereafter, the immune
responses generated in each group were assayed by ex vivo FACS
analysis. Specifically, spleens were excised from four mice in
each group at 4 days post-infection and assayed for a number of
immunological responses known to be associated with
trypanosome infection (Beschin et al., 1998; Millar et al., 1999;
Sternberg and Mabbott, 1996). These included the prevalence of
different classes of immune cells, the apoptosis of lymphocytes,
and expression of interferon-g (IFN-g), interleukin-10 (IL-10) and
Foxp3 by CD4+ and CD8+ T-cells. As expected, there were
consistent differences between the naïve mice and the
trypanosome-infected mice (encompassing WT +DOX, BSF
K9:K69 +DOX and BSF K9:K69 –DOX). Thus, trypanosome
infection generated an increase in the percentage of granulocytes
that were eosinophils (Siglec F+) and neutrophils (Gr-1+), a
decrease in the percentage of lymphocytes that were positive for
CD4 and an increase in apoptosis of CD4+ T-cells. Moreover, an
increase in the production of IFN-g by both CD4+ and CD8+ T-
cells was detected by intracellular cytokine staining (Fig. 8).
Although the responses between trypanosome-infected and naïve
mice reflected expectations, no statistically significant effects on
the host immune response due to the expression of ESAG9 proteins
were observed.
Discussion
ESAGs co-transcribed with the surface coat antigens of the African
trypanosome are believed to contribute to the survival of parasites
in the mammalian bloodstream. Here, we have discovered that one
gene family, previously found contained within a VSG expression
site, is exclusively expressed only in the transmissible bloodstream
stage of the parasite stumpy forms. Further, we have discovered
that many copies of the gene are expressed, at least at the RNA
level, from outside of expression sites, with at least two copies,
ESAG9-K9 and ESAG9-K69, being translated into protein.
Surprisingly, ESAG9 proteins can be released from bloodstream
stumpy forms, and from monomorphic cells expressing both ESAG9-
K9 and ESAG9-K69. This suggests that different ESAG9 proteins
might cooperate to assist trafficking to the flagellar pocket of the
parasite for extracellular release from stumpy forms. Perurbation of
this, either through the expression of a single ESAG9 protein type
in vitro, or during the normal differentiation process, might result in
the accumulation of intracellular ESAG9 protein within the
endoplasmic reticulum, this being visualised as transiently cell-
associated protein during differentiation. Nonetheless, ESAG9
expression in bloodstream stumpy cells appears to be significantly
extracellular, generating the potential for interaction with the
mammalian immune system in chronic infections or providing
function as a pre-adaptation for parasite transmission.
No other secreted proteins in the trypanosomatids have yet been
characterised to this extent. A member of the cyclophilin family,
CypA, is reported to be secreted by bloodstream form Trypanosoma
congolense parasites (Pelle et al., 2002) but a function has not as
yet been definitively ascribed to this protein. Also, Trypanosoma
cruzi shed SAP proteins (Baida et al., 2006), although these are
implicated in host cell invasion and so not relevant to the
extracellular T. brucei. However, it is interesting to note that SAP
proteins share some similarity with the T. cruzi MASP family,
which, in turn, were weakly recognised in BLAST searches using
ESAG9 sequences, but not other ESAGs. MASP proteins are
extensively glycosylated surface proteins with no assigned function;
however, they too have been proposed to be released from T. cruzi
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Fig. 8. Ex vivo FACS analysis using the mouse model of trypanosomiasis.
Mice were inoculated with transgenic (BSF K9.K69) parasites induced
(+DOX) or not induced (–DOX) for the ectopic expression of ESAG9-K9 and
ESAG9-K69. Controls were wild-type monomorphic parasites (WT) or naïve
inoculations (Media). The following traits were assayed: (A) the percentage of
live granulocytes that were Gr-1-positive (neutrophils); (B) the percentage of
live granulocytes that were Siglec F-positive (eosinophils); (C) the percentage
of live lymphocytes that were CD4+; (D) the percentage of CD4+ T-cells that
were undergoing apoptosis (assayed by Annexin V); (E) the percentage of
CD4+ T-cells that were expressing IFN-g, as assayed by intracellular cytokine
staining; and (F) the percentage of CD8+ T-cells that were expressing IFN-g.
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parasites and speculated to modulate host immune regulation
(Bartholomeu et al., 2009).
Similar to the MASP protein family, the sequence of predicted
ESAG9 proteins is remarkably diverse. Indeed, little sequence
identity was recognised between ESAG9 proteins beyond the
presence of an N-terminal signal sequence and potential GPI-
anchor addition site at the C-terminus, which at least in the case of
ESAG9-K9 appeared not be utilised. Nonetheless, a well-conserved
motif was identified in the N-terminal region of the mature protein,
represented by the sequence CX3WX8CX5G. This motif is similar
to one half of the manganese binding motif present in protein
phosphatase type 2 enzymes, and also to the cysteine-rich repeats
in the scavenger receptor-cysteine-rich (SRCR) family of proteins,
which are among the most evolutionarily ancient family of
proteins of the immune system. We also note that the recently
identified trypanosomatid protein, trypanosome-suppressive
immunomodulating factor (TSIF), is a cysteine-rich protein, this
being found to have inflammatory and immunosuppressive proteins
in vitro and in ex vivo assays when expressed as a recombinant
protein (Gomez-Rodriguez et al., 2009). Unfortunately, we have
not succeeded in expressing recombinant ESAG9 protein; however,
our expression of ESAG9 proteins in monomorphic cells under
inducible regulation probably represents the most biologically
appropriate assay for examining the function of ESAG9 proteins
in vivo. Although this has not demonstrated a consistent effect on
immune markers, our experiments do not preclude an
immunomodulatory function for ESAG9 due to the limitations in
what is experimentally tractable. For example, although we were
able to express two copies of ESAG9 proteins in our transgenic
lines, the mRNA expression profile in stumpy forms suggested that
many copies of different ESAG9 proteins are expressed such that
the overall ESAG9 expression levels, or protein repertoire, achieved
in our experiments might have been insufficient. Furthermore, the
necessity of using virulent monomorphic lines, which do not form
stumpy cells and so do not ordinarily express ESAG9 proteins,
meant that immune responses in chronic infections could not be
assayed. These factors, combined with the inability to deplete
the expression of the diverse members of the ESAG9 family
in pleomorphic cells by RNAi, leaves the potential
immunomodulatory function of these protein an open question.
Our experiments provide the first analysis of a diverse family of
ESAGs expressed predominantly in the transmission stage of the
trypanosome. Other ESAG proteins have recently been speculated
to be involved in immune regulation (e.g. ESAG5) and stumpy
forms have been shown to demonstrate novel mechanisms
promoting their survival in the mammalian bloodstream (Engstler
et al., 2007). The expression of ESAG9 proteins might assist the
survival of those cells expressing the proteins, for example, at the
peak of a wave of parasitaemia or during their early establishment
in the fly, where both mammalian and tsetse immune factors might
impact on them. A more intriguing prospect, however, is the
potential for generating an effect on the immune system to enhance
the viable chronicity of trypanosome infections in the field. In this
case, individual parasites, irreversibly division-arrested and doomed
to destruction in the blood, would contribute to sustaining a long-
term infection, either through aiding the survival of the remaining
proliferative parasites, or by ameliorating the potentially damaging
effects of the anti-parasite immune responses on the host. Such a
cooperative action by the parasites would provide an interesting
evolutionary context to stumpy form biology over and above their
role in parasite transmission.
Materials and Methods
Ethics statement
Animal experiments in this work were carried out in accordance with the local ethical
approval requirements of the University of Edinburgh and the UK Home Office Animal
(Scientific Procedures) Act (1986).
Trypanosomes
T. brucei EATRO 2340 monomorphic (GUP2965) or pleomorphic (GUP 2962) were
used both being gifts of Mike Turner at the University of Glasgow, Scotland.
T. brucei AnTat1.1 was a gift of Jay Bangs (University of Wisconsin). Each line was
grown in female Balb/c mice. Monomorphic T. brucei Lister s427 were used in
transgene expression analyses.
Construct generation and production of transgenic cell lines
ESAG9-K9 and ESAG9-K69 were each isolated from a PCR-select subtractive
hybridisation screen between monomorphic slender and stumpy cells of T. brucei
EATRO 2340. ESAG9-K9 and ESAG9-K69 were then PCR amplified from genomic
DNA using primers that added a 5HindIII and 3BamHI site to the native genes
and then cloned into the HindIII/BamHI sites of the trypanosome expression
vector pHD451 (Biebinger et al., 1997). The internal Ty1 epitope tag sequence
(Bastin et al., 1996) was incorporated by annealing separate amplicons of the 5
or 3 half of the genes with the epitope tag sequence being incorporated in to the
3 or 5 end of each half-product respectively. Annealing and amplification using
ESAG9-K9 or ESAG9-K69 forward and reverse primers (incorporating a 5HindIII
site, or 3 BglII site) generated the internally tagged genes, which were validated
by DNA sequencing.
For parasite transfection, 10 g of each construct was transfected in to bloodstream
forms of T. brucei s427 engineered to express the tetracycline repressor protein,
enabling inducible transgene expression. Transformants were selected using either 2
g/ml hygromycin (ESAG9-K9) or 0.5 g ml–1 puromycin (ESAG9-K69).
For parasite differentiation analyses, in vitro grown bloodstream forms in mid-log
growth (4106 ml–1), or stumpy cells harvested from rodents, were supplemented
with cis-aconitate pH 7.0 at a concentration of 6 mM. Samples for
immunofluorescence were harvested and analysed as described previously (Tasker
et al., 2000) and the images processed using Adobe Photoshop 7.
Conditioned media was generated by growing cells in either HMI-9 media
supplemented with 5% FCS or serum-free media. The parasites were removed by
centrifugation and the resulting supernatant filtered through a 0.20 m filter and
concentrated by centrifugation through Vivaspin columns with a 10 kDa cut-off
(Sartorius).
Protein, RNA analyses
Protein and RNA purification was carried out as described (Tasker et al., 2000).
Genomic DNA was prepared as described (MedinaAcosta and Cross, 1993). Western
blotting and northern blotting were each carried out as described (Tasker et al.,
2000). Antibodies to ESAG9-K9 and ESAG9-K69 were raised to the relevant
peptides and affinity purified against the immunogens (Eurogentec, Belgium).
N-Glycosylation analysis
Some 6107 bloodstream form cells were harvested by centrifugation, lysed, and
incubated in the presence or absence or PNGase-F according to the manufacturer’s
instructions (New England Biosciences).
Immunoprecipitation
Prior to the immunoprecipitation, the required volume of antibody was incubated for
30 minutes with 10 g of the blocking peptide or with an equivalent volume of
buffer. The antibody was then incubated with cell lysate for one hour at 4°C. An
equivalent volume of Protein G beads (Sigma) was added and incubated for 1 hour
at 4°C. The G beads were washed and the protein eluted by boiling in Laemmli
buffer.
Ex vivo FACS analysis
Red blood cell lysed spleen cell samples were surface-stained with FITC-conjugated
-CD4 (BioLegend), phycoerythrin (PE)-conjugated -CD8 (BD Pharmingen),
Alexa Fluor 488-conjuated -F4/80 (Caltag Laboratories), PE-conjugated -Siglec
F (BD Pharmingen), Biotin-conjugated -Gr-1 in combination with Streptavidin
APC (BD Pharmingen), PerCP-conjugated -B220 (BD Pharmingen), APC-
conjugated -Annexin V (BD Pharmingen), APC-conjugated -IL-10 (Pharmingen)
and PE-conjugated -FoxP3 (eBioscience). For intracellular cytokine staining, 5106
spleen cells were incubated with 0.5 g/ml phorbol myristate acetate (Sigma) and 1
g/ml Ionomycin (Sigma) for 1 hour at 37°C, 5% CO2 before treatment with 10
g/ml of the protein transport inhibitor Brefeldin A (Sigma) for a following 3 hours.
Cells were then surface-stained with anti-CD4 and anti-CD8 prior to intracellular
staining using e-Bioscience fixation and permeabilisation buffers and APC-conjugated
anti-IFN-g (BD Pharmingen). 100,000 cells from each sample were analysed using
a FACScalibur machine (Beckton Dickinson) and the data analysed with FlowJo
software (Tree Star).
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